RxDoctor Payments Data

Kimball Fuiks, MD

Neurological Surgery · Brookfield, WINPI 1932170362

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,711 of the $3,692 with a category attached, or 73.4%. 16 manufacturers reported payments, led by Medtronic at 40.5% of the total. Reporting peaked in 2019 at $1,292 and has fallen 94.8% since, to $67 in 2024.

$3,692in general payments, 2019–2025

Across 65 payments — averaging $56.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Si-bone, Inc.$1K
  • Seaspine Orthopedics Corporation$317
  • Medicrea USA, Corp.$195
  • Cerapedics Inc.$175
  • Arbor Pharmaceuticals, Inc.$95
  • plus $250 from 10 others

What the payments were for

  • Travel & lodging$98127%
  • Food & beverage$2,71173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,692 in reported general payments places this provider in the 65th percentile of 133 neurological surgery providers in Wisconsin.

See all neurological surgery providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,007
Medicare patients
42
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide21$54,736
Fentanyl37$6,784
Oxycodone Hcl175$5,713
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$3,845
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$2,957
Gabapentin139$2,412
Morphine Sulfate ErMorphine Sulfate42$1,993
Tizanidine Hcl92$1,740
Triazolam13$1,616
Methadone Hcl12$1,216
Doxycycline Hyclate13$1,196
Levetiracetam34$1,050
CefuroximeCefuroxime Axetil11$905
Phenytoin Sodium Extended12$781
Pregabalin18$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$16$54,73621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 133 neurological surgery providers in Wisconsin.

Other neurological surgery in Brookfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →